CAMBRIDGE, Mass., May 4, 2011 /PRNewswire/ -- InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), and The University of Miami Miller School of Medicine's Miami Project to Cure Paralysis, the world's most comprehensive spinal cord injury research center, today announced a strategic research collaboration for the development of novel SCI treatments.
The collaboration will evaluate InVivo's biopolymer devices synergistically combined with cellular therapies, including The Miami Project's Schwann cell technologies. Key components of the research collaboration agreement include:
"This collaboration provides a tremendous opportunity for our technology platform," said Frank Reynolds, CEO of InVivo Therapeutics. "To date, InVivo has been focused primarily on acute spinal cord injury research, and this partnership, which comes shortly before we file an Investigational Device Exemption for our first acute technology, will allow us to advance these technologies to the chronic spinal cord injury population with the Miami Project. The leadership of Nick and Marc Buoniconti has helped form what has become the world's preeminent center of excellence for SCI research. We are honored to have them behind our efforts at InVivo and look forward to tapping their expertise to help us with our products," said Frank Reynolds, CEO of InVivo Therapeutics.
InVivo's biopolymer scaffoldings mimic the natural and protective properties of the extracellular matrix within the spinal cord to promote the proliferation and survival of implanted cells. In preclinical studies
|SOURCE The Miami Project; InVivo Therapeutics|
Copyright©2010 PR Newswire.
All rights reserved